^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CSF1R fusion

    i
    Other names: CSF1R, C-FMS, CD115, CSFR, FMS, Colony stimulating factor 1 receptor
    Entrez ID:
    1436
    Related biomarkers:
    Expression
    Fusion
    6ms
    Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131 (ASH 2023)
    These patients are predicted to be sensitive to ABL-class tyrosine kinase inhibitors, such as imatinib or dasatinib. Patients with ABL-class fusions were more likely male, EOI MRD+, and had poorer outcomes. Seventy-seven percent of patients enrolled on the Dasatinib arm did not complete prescribed therapy. While dasatinib was well tolerated, treatment failures occurred early, indicating alternate strategies are needed.
    Clinical
    |
    ABL1 (ABL proto-oncogene 1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase) • CSF1R (Colony stimulating factor 1 receptor)
    |
    ABL2 fusion • ABL1 fusion • CSF1R fusion
    |
    dasatinib • imatinib
    7ms
    Acute leukemia with predominantly myeloid differentiation and TBL1XR1::CSF1R fusion. (PubMed, Blood)
    No abstract available
    Journal
    |
    CSF1R (Colony stimulating factor 1 receptor) • TBL1XR1 (TBL1X Receptor 1)
    |
    CSF1R fusion